Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-12-03T00:28:56.303Z Has data issue: false hasContentIssue false
  • English
  • Français

Implementation of Bright Light Therapy as Adjuvant Treatment for Depression and Insomnia Among Inpatients

Published online by Cambridge University Press:  15 April 2020

V. Hantelius ,
S. Steingrimsson ,
E. Christodoulou  and
Z. Szabó
V. Hantelius
Affiliation:
Clinical Department of Psychiatry, Sahlgrenska University Hospital, Gothenburg, Sweden
S. Steingrimsson
Affiliation:
Centre of Ethics Law and Mental Health (CELAM), Sahlgrenska Academy, Gothenburg, Sweden
E. Christodoulou
Affiliation:
Clinical Department of Psychiatry, Sahlgrenska University Hospital, Gothenburg, Sweden
Z. Szabó
Affiliation:
Clinical Department of Psychiatry, Sahlgrenska University Hospital, Gothenburg, Sweden

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Several effective treatment alternatives exist for depression, however, not everyone responds to antidepressants and the time lag to response can be long. Bright light therapy (BLT) has successfully been used as an adjuvant treatment to antidepressants in severe depression among inpatients.

Aim

The aim of this study was to evaluate the implementation of BLT as an adjuvant treatment among inpatients with depression.

Methods

BLT was introduced as an adjuvant therapy to patients admitted to a psychiatric department in October 2013. The protocol included exposure to 10,000 lux for 30 minutes every day for one week. The first 18 patients completing BLT were compared to 36 inpatient-controls matched for age, sex and diagnosis. All participants filled in Montgomery-Åsberg Depression Rating Scale (MADRS-S) and Insomnia Severity Index (ISI).

Results

The groups did not differ in age, sex or diagnosis. The mean MADRS-S end score was 27 points for the BLT-group and 13 point on the ISI compared to 23 and 13 for the control group (p=0.52 and p=0.89, respectively). The mean length of stay was 16 days for the BLT-group and 19 for the control group (p=0.60). The daily dosage of diazepam was 4.3 mg/day in the BLT-group compared to 4.8 mg/day in the control group (p=0.73).

Conclusion

There was no statistically significantly decrease in length of stay in patients treated with BLT. Although the results are non-conclusive from this historical comparison, BLT may provide shorter length of stay and decrease the need for benzodiazepines.

Type
Article: 0633
Information
European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
Copyright
Copyright © European Psychiatric Association 2015
Submit a response

Comments

No Comments have been published for this article.